Skip to content

US · IMA · BIOTECHNOLOGY

ImageneBio Inc (IMA) intrinsic value and stock valuation

$3.92as of 2026-11-21 · Mkt cap 64.18M

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

ImageneBio Inc DCF and intrinsic value

InvestorsCraft values IMA with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from IMA’s statements →

ImageneBio Inc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92130 inmagenebio.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$800K-38.6% 5y CAGRd
20182025
Net income
-$-45.35M
20182025
Free cash flow
-$-47.84M
20182025
Total equity
$133.1M
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$800K$3.5M$9.16M$15.6M$31M
Operating income-$-48.45M-$-37M-$-75.42M-$-70.9M-$-34.14M
Net income-$-45.35M-$-36.57M-$-68.17M-$-68.77M-$-34.12M
EPSd-$-9.31M-$-757.77K-$-1.63M-$-1.9M-$-948.3K
Operating cash flow-$-47.84M-$-46M-$-79.74M-$-74.11M-$-60.25M
Capital expenditure$0.00$0.00-$-410K-$-1.43M-$-1.76M
Free cash flow-$-47.84M-$-46M-$-80.16M-$-75.54M-$-62.01M
Total assets$153M$141.5M$192.1M$172.3M$247.9M
Total debt$9.99M$7.52M$10.7M$5.69M$6.99M
Net debt-$-24.97M-$-31.87M-$-109.16M-$-54.23M-$-225.23M
Total equity$133.1M$125.9M$169.8M$147M$207.9M
Cash and short-term investments$75.8M$124.4M$175.5M$157M$232.2M
Income statement
20252024202320222021
Revenue$800K$3.5M$9.16M$15.6M$31M
Cost of revenue$1.03M$1.53M$1.02M$64.3M$47.1M
Gross profit-$-230K$1.97M$8.14M-$-48.7M-$-16.12M
Research and development expenses$28.5M$32.1M$59.7M$64.3M$47.1M
Selling, general and administrative expenses$20.7M$8.39M$24.9M$22.2M$18M
Other expenses-$-1.03M-$-1.53M-$-1.02M-$-64.32M-$-47.11M
Operating expenses$48.2M$39M$83.6M$22.2M$18M
Cost and expenses$49.3M$40.5M$84.6M$86.5M$65.1M
Interest income$2.04M$7.37M$7.11M$2.15M$20K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$1.03M$1.53M$1.02M$750K$540K
Ebitda-$-44.67M-$-35.03M-$-67.31M-$-68.01M-$-33.57M
Operating income-$-48.45M-$-37M-$-75.42M-$-70.9M-$-34.14M
Total other income/expenses, net$2.75M$450K$7.09M$2.14M$20K
Income before tax-$-45.7M-$-36.55M-$-68.33M-$-68.77M-$-34.12M
Income tax expense-$-350K$10K-$-160K$0.00$0.00
Net income-$-45.35M-$-36.57M-$-68.17M-$-68.77M-$-34.12M
Weighted average shares outstanding$4.87M$48.3M$41.7M$36.2M$36M
Weighted average diluted shares outstanding$4.87M$48.3M$41.7M$36.2M$36M
Balance sheet
20252024202320222021
Cash and short-term investments$75.8M$124.4M$175.5M$157M$232.2M
Net receivables$1.3M$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$140.3M$127.2M$178.7M$160M$236.5M
Property, plant and equipment, net$790K$4.23M$8.02M$8.46M$8.98M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$2.39M
Total non-current assets$12.7M$14.3M$13.4M$12.3M$11.4M
Total assets$153M$141.5M$192.1M$172.3M$247.9M
Accounts payable$1.44M$900K$2.07M$2.09M$2.38M
Short-term debt$2.26M$3.78M$3.56M$1.91M$1.85M
Deferred revenue$0.00$0.00$0.00$9.16M$17.1M
Total current liabilities$11.2M$10.8M$14.2M$21.5M$27.2M
Long-term debt$7.73M$3.74M$7.18M$3.79M$5.13M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$7.68M
Total non-current liabilities$8.6M$4.8M$8.13M$3.79M$12.8M
Capital lease obligations$2.98M$7.52M$10.7M$5.69M$6.99M
Total liabilities$19.8M$15.6M$22.3M$25.3M$40M
Common stock$10K$50K$50K$40K$40K
Retained earnings-$-230.05M-$-331.62M-$-282.38M-$-214.22M-$-145.45M
Accumulated other comprehensive income (loss)$90K$70K-$-50K-$-760K$0.00
Total equity$133.1M$125.9M$169.8M$147M$207.9M
Total investments$40.8M$85M$55.6M$97M$2.39M
Total debt$9.99M$7.52M$10.7M$5.69M$6.99M
Net debt-$-24.97M-$-31.87M-$-109.16M-$-54.23M-$-225.23M
Cash flow statement
20252024202320222021
Net income-$-52.4M-$-49.23M-$-68.17M-$-68.77M-$-34.12M
Depreciation and amortization$330K$490K$1.02M$750K$540K
Stock-based compensation$15.4M$5.29M$0.00$7.53M$5.18M
Change in working capital-$-19.19M-$-3.98M-$-21.67M-$-15.14M-$-33.03M
Accounts receivable$0.00$0.00$0.00-$-290K$360K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-2.82M-$-1.17M-$-2.87M$0.00$0.00
Net cash provided by operating activities-$-47.84M-$-46M-$-79.74M-$-74.11M-$-60.25M
Investments in property, plant and equipment$0.00$0.00-$-410K-$-1.43M-$-1.76M
Acquisitions, net-$-5.21M$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-5.81M-$-34.9M$64.1M-$-99.28M-$-1.76M
Common stock issued$65.8M$0.00$37.6M$0.00$131.3M
Common stock repurchased$0.00$0.00-$-660K$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$135.5M$0.00$76M$1.09M$131.7M
Net change in cash$82.4M-$-80.91M$60M-$-172.3M$69.7M
Cash at end of period$94.5M$40.3M$119.9M$60.8M$233.1M
Operating cash flow-$-47.84M-$-46M-$-79.74M-$-74.11M-$-60.25M
Capital expenditure$0.00$0.00-$-410K-$-1.43M-$-1.76M
Free cash flow-$-47.84M-$-46M-$-80.16M-$-75.54M-$-62.01M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About ImageneBio Inc

        ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.

        CEO
        Kristin Yarema
        Employees
        15
        Beta
        0.76

        Explore

        Frequently asked questions

        What is the intrinsic value of ImageneBio Inc (IMA)?

        ImageneBio Inc (IMA) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is IMA undervalued?

        IMA trades at a price of $3.92 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.